Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) rapidly infects humans and animals which make coronavirus disease 2019 (COVID-19) a grievous epidemic worldwide which broke out in 2020. According to data analysis of the other coronavirus family, for instance severe acute respiratory...
Saved in:
Main Authors: | Zhi-Mei Liu (Author), Ming-Hui Yang (Author), Kun Yu (Author), Zheng-Xing Lian (Author), Shou-Long Deng (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
by: Lingling Huang, et al.
Published: (2022) -
Toll-like receptor agonists as cancer vaccine adjuvants
by: Donghwan Jeon, et al.
Published: (2024) -
Natural Products with Toll-Like Receptor 4 Antagonist Activity
by: Monica Molteni, et al.
Published: (2018) -
Genetic Variation in Toll-Like Receptors (TLRs) 2, 4, and 9 Influences HIV Disease Progression Toward Active TB and AIDS
by: Kaushik G, et al.
Published: (2024) -
Anti-tumor Activity of Toll-Like Receptor 7 Agonists
by: Huju Chi, et al.
Published: (2017)